Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism
Purpose: We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479). Methods: We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2024-02-01
|
| Series: | European Thyroid Journal |
| Subjects: | |
| Online Access: | https://etj.bioscientifica.com/view/journals/etj/13/1/ETJ-23-0175.xml |
| _version_ | 1797319312188375040 |
|---|---|
| author | Camilla Bøgelund Larsen Kristian Hillert Winther Per Karkov Cramon Åse Krogh Rasmussen Ulla Feldt-Rasmussen Nils Jakob Knudsen Jakob Bue Bjorner Lutz Schomburg Kamil Demircan Thilo Samson Chillon Jeppe Gram Stinus Gadegaard Hansen Frans Brandt Birte Nygaard Torquil Watt Laszlo Hegedüs Steen Joop Bonnema |
| author_facet | Camilla Bøgelund Larsen Kristian Hillert Winther Per Karkov Cramon Åse Krogh Rasmussen Ulla Feldt-Rasmussen Nils Jakob Knudsen Jakob Bue Bjorner Lutz Schomburg Kamil Demircan Thilo Samson Chillon Jeppe Gram Stinus Gadegaard Hansen Frans Brandt Birte Nygaard Torquil Watt Laszlo Hegedüs Steen Joop Bonnema |
| author_sort | Camilla Bøgelund Larsen |
| collection | DOAJ |
| description | Purpose: We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479).
Methods: We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment. QoL, assessed by the Thyroid-related Patient-Reported-Outcome questionnaire (ThyPRO-39), was measured at baseline, after 6 weeks, and after 3, 6, 12, and 18 months.
Results: In total, 332 patients (81%) completed the intervention period, of whom 82% were women. Although QoL improved during the trial, no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention. In addition, employing linear mixed model regression no difference between the two groups was observed in the ThyPRO-39 composite score (28.8 (95% CI: 24.5–33.6) and 28.0 (24.5–33.1), respectively; P = 0.602). Stratifying the patients according to duration of the disease at inclusion, ThyPRO-39 composite score, TPOAb level, or selenium status at baseline did not significantly change the results. TPOAb levels after 12 months of intervention were lower in the selenium group than in the placebo group (1995 (95% CI: 1512–2512) vs 2344 kIU/L (1862–2951); P = 0.016) but did not influence LT4 dosage or free triiodothyronine–free thyroxine ratio.
Conclusion: In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent. |
| first_indexed | 2024-03-08T04:05:05Z |
| format | Article |
| id | doaj.art-dd77d67b749f4052b7f7503de268b16a |
| institution | Directory Open Access Journal |
| issn | 2235-0802 |
| language | English |
| last_indexed | 2024-03-08T04:05:05Z |
| publishDate | 2024-02-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | European Thyroid Journal |
| spelling | doaj.art-dd77d67b749f4052b7f7503de268b16a2024-02-09T07:15:27ZengBioscientificaEuropean Thyroid Journal2235-08022024-02-01131113https://doi.org/10.1530/ETJ-23-0175Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidismCamilla Bøgelund Larsen0Kristian Hillert Winther1Per Karkov Cramon2Åse Krogh Rasmussen3Ulla Feldt-Rasmussen4Nils Jakob Knudsen5Jakob Bue Bjorner6Lutz Schomburg7Kamil Demircan8Thilo Samson Chillon9Jeppe Gram10Stinus Gadegaard Hansen11Frans Brandt12Birte Nygaard13Torquil Watt14Laszlo Hegedüs15Steen Joop Bonnema16Department of Endocrinology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, DenmarkDepartment of Clinical Research, University of Southern Denmark, Odense, DenmarkDepartment of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkDepartment of Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkDepartment of Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Institute of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen University, Copenhagen, Denmark Department of Endocrinology, Bispebjerg University Hospital, Copenhagen, DenmarkDepartment of Public Health, Copenhagen University, Copenhagen, Denmark; QualityMetric Inc, Johnston, Lincoln, Rhode Island, USAInstitute for Experimental Endocrinology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyInstitute for Experimental Endocrinology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyInstitute for Experimental Endocrinology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyMedical Department, Endocrinology, University Hospital of South-West Jutland, Esbjerg, DenmarkMedical Department, Endocrinology, University Hospital of South-West Jutland, Esbjerg, DenmarkDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark; Internal Medicine Research Unit, University Hospital of Southern Jutland, Aabenraa, Denmark Department of Endocrinology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, DenmarkDepartment of Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Institute of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen University, Copenhagen, Denmark Department of Endocrinology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, DenmarkDepartment of Endocrinology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, DenmarkPurpose: We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479). Methods: We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment. QoL, assessed by the Thyroid-related Patient-Reported-Outcome questionnaire (ThyPRO-39), was measured at baseline, after 6 weeks, and after 3, 6, 12, and 18 months. Results: In total, 332 patients (81%) completed the intervention period, of whom 82% were women. Although QoL improved during the trial, no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention. In addition, employing linear mixed model regression no difference between the two groups was observed in the ThyPRO-39 composite score (28.8 (95% CI: 24.5–33.6) and 28.0 (24.5–33.1), respectively; P = 0.602). Stratifying the patients according to duration of the disease at inclusion, ThyPRO-39 composite score, TPOAb level, or selenium status at baseline did not significantly change the results. TPOAb levels after 12 months of intervention were lower in the selenium group than in the placebo group (1995 (95% CI: 1512–2512) vs 2344 kIU/L (1862–2951); P = 0.016) but did not influence LT4 dosage or free triiodothyronine–free thyroxine ratio. Conclusion: In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent.https://etj.bioscientifica.com/view/journals/etj/13/1/ETJ-23-0175.xmlhypothyroidismautoimmune thyroiditishealth-related quality of lifeselenium supplementation |
| spellingShingle | Camilla Bøgelund Larsen Kristian Hillert Winther Per Karkov Cramon Åse Krogh Rasmussen Ulla Feldt-Rasmussen Nils Jakob Knudsen Jakob Bue Bjorner Lutz Schomburg Kamil Demircan Thilo Samson Chillon Jeppe Gram Stinus Gadegaard Hansen Frans Brandt Birte Nygaard Torquil Watt Laszlo Hegedüs Steen Joop Bonnema Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism European Thyroid Journal hypothyroidism autoimmune thyroiditis health-related quality of life selenium supplementation |
| title | Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism |
| title_full | Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism |
| title_fullStr | Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism |
| title_full_unstemmed | Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism |
| title_short | Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism |
| title_sort | selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism |
| topic | hypothyroidism autoimmune thyroiditis health-related quality of life selenium supplementation |
| url | https://etj.bioscientifica.com/view/journals/etj/13/1/ETJ-23-0175.xml |
| work_keys_str_mv | AT camillabøgelundlarsen seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT kristianhillertwinther seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT perkarkovcramon seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT asekroghrasmussen seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT ullafeldtrasmussen seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT nilsjakobknudsen seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT jakobbuebjorner seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT lutzschomburg seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT kamildemircan seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT thilosamsonchillon seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT jeppegram seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT stinusgadegaardhansen seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT fransbrandt seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT birtenygaard seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT torquilwatt seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT laszlohegedus seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism AT steenjoopbonnema seleniumsupplementationandplaceboareequallyeffectiveinimprovingqualityoflifeinpatientswithhypothyroidism |